Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

January 22, 2020

Conditions
Hodgkin LymphomaNon-Hodgkin LymphomaLymphoproliferative DisorderNasopharyngeal CarcinomaLeiomyosarcomaSevere Chronic Active EBV (SCAEBV)
Interventions
BIOLOGICAL

LMP specific T cells

"Three dose levels will be evaluated:~Dose Level 1: 2×10\^7 cells/m2; Dose Level 2: 1×10\^8 cells/m2; Dose Level 3: 2×10\^8 cells/m2~If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection."

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT01447056 - Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases | Biotech Hunter | Biotech Hunter